Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Phase 1 Completed

83 enrolled

Breast

Triple Negative Breast Neoplasms

NCT00976131 2022-10-17

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Phase 1 Completed

7 enrolled

Breast

Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Phase 1 Completed

45 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02262455 2017-02-13

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT02131506 2016-02-02

CAELYX

Phase 1 Terminated

11 enrolled

Breast

Breast Neoplasms

NCT01815294 2015-12-04

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Phase 1 Completed

54 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT00316875 2013-11-08

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Phase 1 Completed

23 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00290732 2013-10-31

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

Phase 1 Completed

20 enrolled 9 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Doxil/Caelyx BE Study

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

CAELYX

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)